Wegovy Tablet vs Injection: What's the Difference (and When Will the UK Get It)?

Weight loss injections like Wegovy have transformed how obesity is treated. But not everyone wants to inject themselves. The recent approval of an oral Wegovy tablet in the United States has sparked huge interest, particularly among people who would prefer to avoid needles.

So what exactly is the Wegovy tablet? How does it compare to the injection? And when might it become available in the UK?

What is the Wegovy tablet?

The Wegovy tablet is an oral formulation of semaglutide. It's the same active ingredient found in the Wegovy injection. The US Food and Drug Administration approved it in December 2025, and it launched in American pharmacies in early January 2026.

This is the first time a GLP-1 receptor agonist has been approved specifically for weight loss in tablet form. Previously, semaglutide tablets were only available for treating type 2 diabetes under the brand name Rybelsus.

The key details:

Taken once daily

Maximum dose of 25mg

Same active ingredient as the injection

Comparable weight loss results

Weight loss effectiveness: Tablet vs injection

Both formulations work in the same way. They mimic a natural hormone called GLP-1, which helps regulate appetite, slow digestion, and control blood sugar levels.

The OASIS 4 clinical trial showed that the oral tablet produces similar weight loss to the injection. Here's what happened:

Average weight loss with the 25mg tablet: 16.6% of starting body weight over 64 weeks

Average weight loss with the injection: 15-17% in previous studies

One in three people taking the tablet achieved at least 20% weight loss

The results are comparable. Both formulations can deliver significant weight loss when combined with diet and exercise.

How they differ: Dosing schedule

The injection:

Taken once per week

Injected under the skin (stomach, thigh, or upper arm)

Can be taken any day of the week that suits you

Maximum maintenance dose of 2.4mg (or 7.2mg with the new higher dose)

The tablet:

Taken once every morning

Must be on an empty stomach

At least 30 minutes before eating, drinking (except water), or taking other medications

Maximum dose of 25mg daily

Some people prefer the weekly routine. Others find a daily tablet easier to remember and integrate into their morning habits.

Side effects: What to expect

The side effects are similar for both formulations. Most commonly:

Nausea

Vomiting

Diarrhoea

Constipation

Stomach pain

Headache

Feeling tired

In clinical trials, serious adverse events were actually less frequent with the oral tablet (3.9%) compared to placebo (8.8%).

One important difference: the tablet contains SNAC, an absorption enhancer that helps the medication work. This ingredient crosses into the bloodstream and may not be suitable during pregnancy or breastfeeding. The injectable form does not contain SNAC.

Both forms require gradual dose escalation to reduce side effects. For the tablet, you start at 1.5mg and work up to 25mg over 12 weeks.

Convenience: Which fits your lifestyle better?

Advantages of the injection:

Only once per week

No food or drink restrictions

No need to wait before eating breakfast

Does not require refrigeration after first use

Straightforward to use once you get the hang of it

Advantages of the tablet:

No needles

No sharps disposal needed

Better for people who travel frequently

Easier to carry around

May appeal to people with needle phobia

Drawbacks of the tablet:

Must be taken on an empty stomach

30-minute wait before eating or drinking

Can be tricky if you have an early breakfast routine

Not ideal if you take other morning medications

Requires consistent wake-up times

The best choice depends entirely on your personal circumstances and preferences.

Cost: Is the tablet cheaper?

In the United States, Novo Nordisk has positioned the Wegovy tablet as a more affordable option. The starting dose of 1.5mg is available for $149 per month with savings offers, which is lower than the typical cost of the injectable form.

UK pricing has not been announced yet. The tablet is still awaiting regulatory approval. However, if the same pricing strategy is adopted here, it could make treatment more accessible for people paying privately.

The tablet may be cheaper to produce and distribute. It does not require the same cold chain logistics as the injectable pens.

When will the Wegovy tablet be available in the UK?

The Wegovy tablet is not yet approved in the UK. But Novo Nordisk has submitted it to the European Medicines Agency for review. This happened in the second half of 2025.

Expected timeline:

EMA decision: Likely sometime in 2026

UK approval: Possibly late 2026 or early 2027

Private availability: Shortly after MHRA approval

NHS availability: 6-12 months after private launch

The EMA review process typically takes 12 to 18 months for new medications. Once the EMA grants approval, the UK's Medicines and Healthcare products Regulatory Agency will need to complete its own assessment.

Post-Brexit, the MHRA operates independently from the EMA. There may be a slight delay between European approval and UK availability.

When the tablet does become available, it will likely be accessible through private prescriptions first. This has been the case with other weight loss medications. Private clinics and online providers would be able to offer it relatively quickly.

NHS availability would take longer. It requires a separate health technology assessment to determine whether the medication represents good value for the health service.

Who might benefit from the tablet over the injection?

The tablet is not necessarily better than the injection. It is simply a different option.

You might prefer the tablet if you:

Have a strong fear of needles

Struggle with weekly injection routines

Travel frequently and prefer not to carry injection supplies

Already take other medications each morning

Have concerns about injection site reactions

You might prefer the injection if you:

Want a once-weekly routine rather than daily medication

Cannot delay breakfast or morning coffee by 30 minutes

Take other medications first thing in the morning

Are pregnant, planning to become pregnant, or breastfeeding

Prefer not to think about medication every single day

Neither option is inherently superior. The best choice is the one you can stick with consistently over the long term.

What does this mean for weight loss treatment in the UK?

The approval of an oral Wegovy tablet represents an important step forward. Not everyone is comfortable with injections. Having an alternative delivery method could help more people begin and stick with treatment.

However, it is not a replacement for the injection. It is an additional option. Both formulations are effective, and the choice between them will come down to individual preferences, lifestyle factors, and medical suitability.

For now, UK patients will need to wait for regulatory approval. In the meantime, the injectable form remains highly effective and is already accessible both privately and through the NHS for those who meet the eligibility criteria.

As the obesity treatment landscape continues to develop, having multiple options gives clinicians and patients greater flexibility. Whether you prefer a weekly injection or a daily tablet, the most important factor is finding a treatment approach that works for your lifestyle.

Final thoughts

The Wegovy tablet offers comparable weight loss results to the injection. It provides a genuine needle-free alternative for people who would prefer to take a daily tablet rather than a weekly injection.

While the tablet is now available in the United States, UK patients will likely need to wait until late 2026 or 2027 for regulatory approval. Once approved, it is expected to be available through private providers first, with NHS access following later.

If you are currently considering weight loss treatment or are already taking Wegovy injections, speak to your prescribing clinician about which formulation might be most suitable for you once the tablet becomes available in the UK. The best choice will depend on your personal preferences, daily routine, and overall treatment goals.

Reviewed by Irfan Mahmud, Pharmacist and Independent Prescriber (GPhC Reg. No: 2080386)

Irfan is a UK registered pharmacist and independent prescriber with expertise in men's health, weight management and lifestyle medicine. As the founder of Cuva Health, he is dedicated to providing safe, clinically approved treatments and clear, trustworthy health guidance.